Savara has multiple products in various stages of clinical development.
- A Phase 3 clinical trial of Molgradex to treat patients with PAP is currently ongoing worldwide; top-line results are anticipated in the fourth quarter 2018.
- Savara anticipates initiating a pivotal Phase 3 clinical trial of AeroVanc for the treatment of MRSA in cystic fibrosis patients in Q3 of 2017.
- Aironite is currently in clinical studies for the treatment of heart failure with preserved ejection fraction (HFpEF).
Go to products